You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,314,977


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,314,977
Title:Devices, systems and methods for medicament delivery
Abstract: An apparatus includes a housing, a medicament container, an actuator, and a biasing member. The actuator is configured to move the medicament container within the housing when the actuator is moved from a first configuration to a second configuration. The actuator includes a gas container and a puncturer. When the actuator is in the first configuration, a portion of the puncturer is disposed apart from the gas container. When the actuator is in the second configuration, the portion of the puncturer is disposed within the gas container. The gas container has a longitudinal axis offset from a longitudinal axis of the medicament container. The biasing member is configured to bias the actuator toward the second configuration.
Inventor(s): Edwards; Eric S. (Moseley, VA), Edwards; Evan T. (Charlottesville, VA)
Assignee: kaleo, Inc. (Richmond, VA)
Application Number:15/696,287
Patent Claim Types:
see list of patent claims
Device;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,314,977: A Detailed Analysis

Introduction to Patent 10,314,977

United States Patent 10,314,977, hereafter referred to as the '977 patent, is a patent that has been granted by the U.S. Patent and Trademark Office (USPTO). To analyze this patent, it is crucial to understand the broader context of patent law in the United States, particularly the criteria for patent eligibility and the structure of patent claims.

Patent Eligible Subject Matter Under U.S. Law

Patent eligible subject matter in the U.S. is governed by Section 101 of the Patent Act (35 U.S.C. §101), which defines four categories of patentable inventions: processes, machines, manufactures, and compositions of matter[2].

Judicially Developed Exceptions

The Supreme Court has developed judicial exceptions to these categories, which include laws of nature, natural phenomena, and abstract ideas. These exceptions were significantly broadened in recent Supreme Court decisions, such as Bilski v. Kappos, Mayo Collaborative Servs. v. Prometheus Labs., and Alice Corp. v. CLS Bank Int'l[2].

The Alice/Mayo Framework

The '977 patent must comply with the Alice/Mayo framework, a two-step test for determining patent eligibility:

  1. Determine if the claim is directed to a judicial exception: If the claim is directed to an abstract idea, law of nature, or natural phenomenon, it must proceed to the second step.
  2. Determine if the claim adds something more than the judicial exception: The claim must integrate the judicial exception into a practical application, imposing meaningful limits that transform the claim into patent-eligible subject matter[2].

Structure of Patent Claims

Patent claims are the heart of a patent application and define the scope of the invention. The claims in the '977 patent would be structured to include:

  • Independent Claims: These claims stand alone and define the invention without reference to other claims.
  • Dependent Claims: These claims refer back to and further limit the independent claims[1].

Example from Recent Guidance

The 2024 USPTO guidance update on AI patents provides insightful examples. For instance, Claim 1 might involve routine data processing steps that are mere "insignificant extra-solution activity," while Claim 2 specifies the use of separated audio components in a real-time speech recognition system, providing a practical application that transforms the abstract idea into patent-eligible subject matter[4].

Analyzing the '977 Patent

Claim Analysis

To analyze the '977 patent, one must carefully review each claim to determine if it meets the criteria for patent eligibility under the Alice/Mayo framework.

  • Identify Judicial Exceptions: Determine if any claims are directed to abstract ideas, laws of nature, or natural phenomena.
  • Evaluate Practical Applications: Assess if the claims integrate these exceptions into practical applications, providing meaningful limits and tangible benefits.

Practical Applications and Technological Improvements

The '977 patent would need to demonstrate how the claimed invention provides concrete technological improvements. For example, if the patent involves AI-related inventions, the claims must show how the AI is applied in a way that provides specific, practical benefits, such as improving the accuracy of voice commands in hands-free environments[4].

Impact of Recent USPTO Guidance

The 2024 USPTO guidance update on AI patents is particularly relevant if the '977 patent involves AI technology. This guidance clarifies that:

  • AI-Assisted Inventions: The method of invention development, including the use of AI, does not impact subject matter eligibility. The focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[4].
  • Meaningful Limits: Claims must impose meaningful limits on judicial exceptions to transform them into patent-eligible subject matter. This involves specifying the use of the invention in a practical application that provides tangible benefits[4].

Real-World Applications and Benefits

Highlighting the real-world applications of the claimed method or system is crucial for demonstrating patent eligibility. The '977 patent should show how the invention solves specific problems or provides concrete benefits in the relevant field.

Example from the Guidance

For instance, if the '977 patent involves a method for processing audio signals, it must specify how these signals are used in a real-time speech recognition system to enhance accuracy, rather than just manipulating data without a practical application[4].

Legislative and Judicial Developments

The landscape of patent eligibility is continuously evolving due to judicial, administrative, and legislative developments.

  • Supreme Court Decisions: The Supreme Court's reluctance to revisit Section 101 issues has led stakeholders to call for congressional action. Bills such as the Patent Eligibility Restoration Act of 2022 and the Restoring America’s Leadership in Innovation Act of 2021 aim to clarify and potentially reform the standards for patent-eligible subject matter[2].
  • USPTO Guidance: The USPTO's ongoing evaluation of comments and issuance of new guidance, such as the 2024 update on AI patents, reflects the agency's efforts to provide clarity and consistency in patent eligibility determinations[4].

Key Takeaways

  • Patent Eligibility Criteria: The '977 patent must meet the criteria set forth in Section 101 and the Alice/Mayo framework.
  • Practical Applications: Claims must integrate judicial exceptions into practical applications that provide meaningful limits and tangible benefits.
  • AI-Assisted Inventions: The use of AI in invention development does not impact subject matter eligibility, provided there is significant human contribution and practical application.
  • Real-World Benefits: Highlighting real-world applications and benefits is essential for demonstrating patent eligibility.

FAQs

What is the Alice/Mayo framework?

The Alice/Mayo framework is a two-step test used to determine patent eligibility. It involves determining if the claim is directed to a judicial exception and if the claim adds something more than the judicial exception to integrate it into a practical application.

How does the USPTO's 2024 guidance update affect AI patents?

The 2024 USPTO guidance update clarifies that AI-assisted inventions are evaluated on equal footing with other technologies. It emphasizes the importance of specifying practical applications that provide meaningful limits and tangible benefits.

What types of inventions are generally considered patent-eligible under U.S. law?

Under U.S. law, patent-eligible inventions include any new and useful process, machine, manufacture, or composition of matter, as defined by Section 101 of the Patent Act.

Why is it important to specify practical applications in patent claims?

Specifying practical applications is crucial because it helps to integrate judicial exceptions into patent-eligible subject matter, providing meaningful limits and tangible benefits that transform abstract ideas into concrete technological improvements.

How do recent legislative developments impact patent eligibility?

Recent legislative developments, such as proposed bills to reform Section 101, aim to clarify and potentially reform the standards for patent-eligible subject matter, reflecting ongoing efforts to balance innovation incentives with the need for clear and consistent patent eligibility criteria.

Sources

  1. BitLaw: Patent Law in the United States - BitLaw
  2. CRS Reports: Patent-Eligible Subject Matter Reform: An Overview
  3. USPTO: Patent Claims Research Dataset
  4. Mintz: Understanding the 2024 USPTO Guidance Update on AI Patent[1][2][4]

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,314,977

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kaleo Inc AUVI-Q epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 201739-003 Nov 17, 2017 RX Yes No 10,314,977 ⤷  Subscribe Y ⤷  Subscribe
Kaleo Inc AUVI-Q epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 201739-002 Aug 10, 2012 BX RX Yes Yes 10,314,977 ⤷  Subscribe Y ⤷  Subscribe
Kaleo Inc AUVI-Q epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 201739-001 Aug 10, 2012 BX RX Yes No 10,314,977 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.